Alder BioPharmaceuticals, Inc. announced the appointment of Nadia Dac as chief commercial officer (CCO), effective April 8, 2019. She brings more than 25 years of U.S. and global commercial experience with both large and small publicly traded biopharmaceutical companies, with extensive expertise across all commercial functions including marketing, market access and promotion, sales, pipeline management, business development and partnerships. She joins Alder from AbbVie, where she served as vice president of global specialty commercial development. In this role, she was instrumental in driving the optimization of assets within the specialty pipeline portfolio, including the in-licensing and commercial development of the global neuroscience, women’s health, virology and cystic fibrosis portfolios. Prior to AbbVie, Ms. Dac held several roles of increasing responsibility at Novartis, where she was head of the Multiple Sclerosis (MS) franchise, building the sales organization that successfully launched Gilenya®, Extavia® and Ilaris®. Before Novartis, she held several marketing roles, including leading marketing for Biogen’s MS products, Tysabri® and Avonex®, and for Pfizer’s Alzheimer's disease product, Aricept®. Previously, Ms. Dac spent several years in marketing and sales roles at Johnson & Johnson and Eli Lilly and Company.